Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

NORCROSS, Ga., March 29, 2013 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the full year and fourth quarter, ended December 31, 2012. These results are included in the Company's Quarterly Report on Form 10-K, which has been filed with the SEC.

"It was a year of great progress for our Company," said Peter G. Traber , M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics. "We completed a significant fundraising and our stock was listed on the NASDAQ Capital Market earlier in the year, we relocated our headquarters to Norcross, Georgia during the fourth quarter, and we made significant advances developing our fibrosis program. We have continued this progress into 2013, having submitted an IND for GR-MD-02 in January and received the FDA's ok that we could proceed with a Phase 1 clinical trial. We expect to initiate a Phase 1 clinical trial of GR-MD-02 during the second quarter of 2013 in patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis and have engaged CTI Clinical Trial Services to provide services related to this trial. The novel mechanism of action of GR-MD-02, in combination with compelling preclinical data, gives us great hope that this compound may ultimately meet the needs of patients with this deadly disease that currently has no approved therapeutic options."

At December 31, 2012, the Company had $9.4 million of non-restricted cash and cash equivalents available to fund future operations.  The Company believes that with the funds on hand at December 31, 2012, there is sufficient cash to fund core operations and planned research and development through the first quarter of 2014.

For the fourth quarter of 2012, the Company reported a net lo
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Riordan-McKenna Institute ... DO, announced today that the use of sterile, dehydrated amniotic tissue AlphaPATCH™ developed ... an otherwise non-healing surgical knee wound. , The case involved a 78-year-old male, ...
(Date:8/27/2015)... ... 27, 2015 , ... The Kansas City Animal Health Investment ... health companies to hear from animal health companies with the newest technology. Companies ... agreements or distribution contracts. This meeting is one of the only investment ...
(Date:8/27/2015)... Mich. , Aug. 27, 2015  Neogen Corporation ... acquired the stock of United Kingdom ... of microbiological culture media and diagnostic systems. ... grown into a leading provider of microbial testing and ... clinical testing markets. The company currently sells into more ...
(Date:8/27/2015)... CELEBRATION, Fla. , Aug. 27, 2015 ... announced that a patient,s eyes—and life—were saved by doctors ... , working with NNFF, NovaBay Pharmaceuticals and Dr. ... Wound Care Center at Seton Medical Center in ... The successful treatment used a breakthrough approach, pioneered by ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3
... N.J., Oct. 6 NEXCORE Technology, Inc., a,world-class ... an agreement with GI Supply of Camp Hill, ... Wand. Polar Wand is a portable,device that uses ... the gastrointestinal tract in patients resistant to conventional,endoscopic ...
... Environmental,Tectonics Corporation,s (Amex: ETC ) ("ETC" or ... of two (2) BARA-MED(R) XD,Monoplace Hyperbaric Chambers to ... delighted to work with Saint Barnabas Medical Center, ... one of the largest health care providers in ...
... BioMed Realty Trust, Inc.,(NYSE: BMR ) today ... its over-allotment option in full to purchase an ... BioMed,s previously,announced offering that priced on October 1, ... common stock, raising net proceeds of,approximately $212.4 million ...
Cached Biology Technology:NEXCORE Technology Selected to Manufacture New Endoscopic Cryotherapy Device 2Environmental Tectonics Corporation Announces the Placement of Two Monoplace Hyperbaric Chambers at Saint Barnabas Medical Center in New Jersey 2Environmental Tectonics Corporation Announces the Placement of Two Monoplace Hyperbaric Chambers at Saint Barnabas Medical Center in New Jersey 3Environmental Tectonics Corporation Announces the Placement of Two Monoplace Hyperbaric Chambers at Saint Barnabas Medical Center in New Jersey 4BioMed Realty Trust Announces Exercise of Over-Allotment Option 2BioMed Realty Trust Announces Exercise of Over-Allotment Option 3
(Date:7/31/2015)... de julho de 2015 A 10 a. ... será realizada pela BGI de 22-25 de outubro de 2015, ... A conferência está celebrando seu 10 o. aniversário ... se tornou uma das reuniões mais influentes do mundo ... mais dinâmicos, entusiastas e prazerosos. A ...
(Date:7/31/2015)... 2015 La 10 th International Conference on ... BGI del 22 al 25 de octubre de 2015 en ... la conferencia celebra su décimo aniversario. Desde su inauguración en ... las reuniones anuales más influyentes del mundo en el campo ... entusiastas y mejores a nivel científico. ICG-10 ...
(Date:7/31/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND SYSTEM ... crypto-currencies such as Bitcoin into the consumer market of ... manage all payments.  The technology manages ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... ear. Sylvia Plath stuck her head in the oven. History ... ways. Were these artists simply mad or brilliant? According to ... of the Association for Psychological Science, maybe both. In ... Szabolcs Kri of Semmelweis University in Hungary focused his research ...
... first experiences with exotic species in the Basque Country, ... concretely in Laukiz, Lezama and Alonsotegui (Muro, 1975) where ... expansion of rapid growth plantations such as those of ... of the growing paper pulp industry. Blights and diseases ...
... MADISON, WI, SEPTEMBER 28, 2009 -- Emphasizing cross-disciplinary ... mass-volume relationships, can help undergraduates learn real-world, problem-solving ... soil science careers. Drs. Josh Heitman and ... Department, highlighted this need for quantitative measurement skills ...
Cached Biology News:Mad genius: Study suggests link between psychosis and creativity 2Canker disease in eucalyptus in the Basque Country 2Canker disease in eucalyptus in the Basque Country 3Canker disease in eucalyptus in the Basque Country 4Help students think like soil scientists 2Help students think like soil scientists 3
... the first biological reagent that ... and not just by inhibiting ... anti-mycoplasma agent that can be ... directly. The cytotoxicity of Mynox ...
A component of the Acridinium protein labeling kit....
... can be used to label ... covalently bound acridinium NHS ester ... presence of hydrogen peroxide. Acridinium ... used as a detection method ...
... Guava is making flow cytometry accessible to anyone ... appreciate the latest addition to Guavas on-demand microcapillary ... easy to use, surprisingly affordable, very compact, ... 3-color detection. The Guava EasyCyte Mini has all ...
Biology Products: